Abstract
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have